Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials

Guru Sonpavde, Gregory R. Pond, Ronan Fougeray, Toni K. Choueiri, Angela Q. Qu, David J. Vaughn, Guenter Niegisch, Peter Albers, Nicholas D. James, Yu Ning Wong, Yoo Joung Ko, Srikala S. Sridhar, Matthew D. Galsky, Daniel P. Petrylak, Ulka N. Vaishampayan, Awais Khan, Nicholas J. Vogelzang, Tomasz (Tom) Beer, Walter M. Stadler, Peter H. O'DonnellCora N. Sternberg, Jonathan E. Rosenberg, Joaquim Bellmunt

    Research output: Contribution to journalArticle

    67 Citations (Scopus)

    Abstract

    Background: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) 0, LM, Hb 0, Hb

    Original languageEnglish (US)
    Pages (from-to)717-723
    Number of pages7
    JournalEuropean Urology
    Volume63
    Issue number4
    DOIs
    StatePublished - Apr 2013

    Fingerprint

    Hemoglobins
    Carcinoma
    Drug Therapy

    Keywords

    • Hemoglobin
    • Liver metastasis
    • Performance status
    • Prognosis
    • Second line
    • Time from prior chemotherapy
    • Urothelial carcinoma

    ASJC Scopus subject areas

    • Urology

    Cite this

    Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma : A retrospective analysis of pooled, prospective phase 2 trials. / Sonpavde, Guru; Pond, Gregory R.; Fougeray, Ronan; Choueiri, Toni K.; Qu, Angela Q.; Vaughn, David J.; Niegisch, Guenter; Albers, Peter; James, Nicholas D.; Wong, Yu Ning; Ko, Yoo Joung; Sridhar, Srikala S.; Galsky, Matthew D.; Petrylak, Daniel P.; Vaishampayan, Ulka N.; Khan, Awais; Vogelzang, Nicholas J.; Beer, Tomasz (Tom); Stadler, Walter M.; O'Donnell, Peter H.; Sternberg, Cora N.; Rosenberg, Jonathan E.; Bellmunt, Joaquim.

    In: European Urology, Vol. 63, No. 4, 04.2013, p. 717-723.

    Research output: Contribution to journalArticle

    Sonpavde, G, Pond, GR, Fougeray, R, Choueiri, TK, Qu, AQ, Vaughn, DJ, Niegisch, G, Albers, P, James, ND, Wong, YN, Ko, YJ, Sridhar, SS, Galsky, MD, Petrylak, DP, Vaishampayan, UN, Khan, A, Vogelzang, NJ, Beer, TT, Stadler, WM, O'Donnell, PH, Sternberg, CN, Rosenberg, JE & Bellmunt, J 2013, 'Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials', European Urology, vol. 63, no. 4, pp. 717-723. https://doi.org/10.1016/j.eururo.2012.11.042
    Sonpavde, Guru ; Pond, Gregory R. ; Fougeray, Ronan ; Choueiri, Toni K. ; Qu, Angela Q. ; Vaughn, David J. ; Niegisch, Guenter ; Albers, Peter ; James, Nicholas D. ; Wong, Yu Ning ; Ko, Yoo Joung ; Sridhar, Srikala S. ; Galsky, Matthew D. ; Petrylak, Daniel P. ; Vaishampayan, Ulka N. ; Khan, Awais ; Vogelzang, Nicholas J. ; Beer, Tomasz (Tom) ; Stadler, Walter M. ; O'Donnell, Peter H. ; Sternberg, Cora N. ; Rosenberg, Jonathan E. ; Bellmunt, Joaquim. / Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma : A retrospective analysis of pooled, prospective phase 2 trials. In: European Urology. 2013 ; Vol. 63, No. 4. pp. 717-723.
    @article{3187d4c79ddf473ba119ba35cef803ac,
    title = "Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials",
    abstract = "Background: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) 0, LM, Hb 0, Hb",
    keywords = "Hemoglobin, Liver metastasis, Performance status, Prognosis, Second line, Time from prior chemotherapy, Urothelial carcinoma",
    author = "Guru Sonpavde and Pond, {Gregory R.} and Ronan Fougeray and Choueiri, {Toni K.} and Qu, {Angela Q.} and Vaughn, {David J.} and Guenter Niegisch and Peter Albers and James, {Nicholas D.} and Wong, {Yu Ning} and Ko, {Yoo Joung} and Sridhar, {Srikala S.} and Galsky, {Matthew D.} and Petrylak, {Daniel P.} and Vaishampayan, {Ulka N.} and Awais Khan and Vogelzang, {Nicholas J.} and Beer, {Tomasz (Tom)} and Stadler, {Walter M.} and O'Donnell, {Peter H.} and Sternberg, {Cora N.} and Rosenberg, {Jonathan E.} and Joaquim Bellmunt",
    year = "2013",
    month = "4",
    doi = "10.1016/j.eururo.2012.11.042",
    language = "English (US)",
    volume = "63",
    pages = "717--723",
    journal = "European Urology",
    issn = "0302-2838",
    publisher = "Elsevier",
    number = "4",

    }

    TY - JOUR

    T1 - Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma

    T2 - A retrospective analysis of pooled, prospective phase 2 trials

    AU - Sonpavde, Guru

    AU - Pond, Gregory R.

    AU - Fougeray, Ronan

    AU - Choueiri, Toni K.

    AU - Qu, Angela Q.

    AU - Vaughn, David J.

    AU - Niegisch, Guenter

    AU - Albers, Peter

    AU - James, Nicholas D.

    AU - Wong, Yu Ning

    AU - Ko, Yoo Joung

    AU - Sridhar, Srikala S.

    AU - Galsky, Matthew D.

    AU - Petrylak, Daniel P.

    AU - Vaishampayan, Ulka N.

    AU - Khan, Awais

    AU - Vogelzang, Nicholas J.

    AU - Beer, Tomasz (Tom)

    AU - Stadler, Walter M.

    AU - O'Donnell, Peter H.

    AU - Sternberg, Cora N.

    AU - Rosenberg, Jonathan E.

    AU - Bellmunt, Joaquim

    PY - 2013/4

    Y1 - 2013/4

    N2 - Background: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) 0, LM, Hb 0, Hb

    AB - Background: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) 0, LM, Hb 0, Hb

    KW - Hemoglobin

    KW - Liver metastasis

    KW - Performance status

    KW - Prognosis

    KW - Second line

    KW - Time from prior chemotherapy

    KW - Urothelial carcinoma

    UR - http://www.scopus.com/inward/record.url?scp=84874550179&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84874550179&partnerID=8YFLogxK

    U2 - 10.1016/j.eururo.2012.11.042

    DO - 10.1016/j.eururo.2012.11.042

    M3 - Article

    C2 - 23206856

    AN - SCOPUS:84874550179

    VL - 63

    SP - 717

    EP - 723

    JO - European Urology

    JF - European Urology

    SN - 0302-2838

    IS - 4

    ER -